Repurposing of Metformin as a Multifaceted and Multitasking Preventative and Treatment for Cancer by Chang, Raymond
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Repurposing of Metformin as a 
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Metformin is a cornerstone treatment of diabetes mellitus. Since 2005 when 
it has been first reported to reduce the risk of cancer in diabetics, a large number 
of preclinical and clinical studies have implicated its potential role as a preventa-
tive and adjunct therapy for a broad range of cancers. Whereas preclinical studies 
demonstrate its actions on a multitude of molecular pathways involving nearly all 
aspects of cancer development including metabolism, angiogenesis, apoptosis, 
autophagy, immunity, epigenetics, inflammation and crosstalk with the microbi-
ome, other studies demonstrate its synergism with a range of anticancer modalities 
including chemotherapy, radiotherapy, immunotherapy, and targeted therapies. 
Furthermore, an increasing number of clinical studies not only confirm its pre-
ventative properties against cancers but have extended its potential for a possible 
adjunctive role in the neoadjuvant, adjuvant, maintenance and salvage therapies of 
cancer. This article intends to summarize the basic science that allows us to under-
stand the complex multiple mechanisms of action of this remarkable multitasking 
molecule as well as review the recent meta-analyses that have summarized the 
clinical studies assessing the therapeutic efficacy of metformin for various cancers.
Keywords: metformin, diabetes, repurposing, cancer therapy
1. Introduction
Metformin is derived from the French lilac (also known as goat’s rue or Gallega 
Officinalis), a medieval European medicinal herb that was first described as a diabetes 
treatment in a mid-17th century English treatise called Culperper’s Complete Herbal, 
but it was not until 1957 that the French physician Jean Sterne formally patented met-
formin as a drug treatment for diabetes. The efficacy of metformin for type 2 diabetes 
mellitus (T2DM) has since been established and it was approved by the US FDA in 
1995 as a treatment for T2DM. Meanwhile by the late 1980’s, studies on the effects of 
metformin on insulin receptor binding on tumor cells led researchers to conceive that 
metformin’s effect may potentially be applied for cancer management [1]. Separately, 
it has long been suspected that T2DM may be a risk for cancer with its cancer promot-
ing effects believed due to hyperinsulinemia in T2DM, since insulin was believed 
to exert a mitogenic effect [2], thus it was simply logical to investigate the potential 
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benefits of an insulin lowering and hence counter-mitogenic anti-diabetic agent for its 
possible anti-cancer effects. By the early 2000’s, studies have already established the 
potential benefits of metformin on hyperinsulinemia, obesity, hyperlipemia, hyper-
tension, fibrinolysis, and endothelial dysfunction, with the expansion of the drug’s 
potential applicability beyond T2DM to address weight gain, acanthosis nigricans, 
infertility and polycystic ovary syndrome [3]. In 2005, a landmark retrospective case 
control study by Evans et al. demonstrated that metformin exposure in T2DM was 
associated with the reduced risk of cancers [4] and further epidemiological studies 
Figure 1. 
Research development of metformin as anticancer agent: Since early epidemiologic reports suggesting metformin 
use in type 2 diabetes was associated with reduced cancer incidence, research evidence that metformin may 
be preventive and/or therapeutic for human cancers has expanded, with most of the molecular and clinical 
breakthroughs in metformin and cancer have taken place during the past decades, and hundreds of clinical 
trials are currently exploring metformin’s potential in cancer. Source: [5], Licensed under CC BY 3.0.
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also corroborated that diabetics treated with metformin have a lowered incidence of 
cancer than those treated with other agents, leading to increasing calls for the use of 
metformin to reduce the risk of cancer. In the past decade, metformin has seen over 50 
million prescriptions per year in the US alone and there has been a concurrent explo-
sion of interest in metformin’s anticancer effects with dozens of systematic reviews 
and meta-analyses performed and published on hundreds of cancer studies involving 
hundreds of thousands of patients and with hundreds of clinical trials on metformin 
and cancer currently actively recruiting. The development and expansion of research 
into metformin’s anticancer activities in the past two decades from the bench to the 
clinic is illustrated below in Figure 1.
Given that this review is intended as a summary of current clinical evidence 
for the potential uses of metformin in the prevention and treatment of cancer, we 
will provide only a succinct synthesis of the thousands of preclinical studies on the 
biological mechanisms and molecular pathways that has been performed in the past 
two decades and focus our attention mostly on recent clinical evidence of metfor-
min’s efficacy as demonstrated by clinical studies.
2. Pleiotropic effects of metformin against cancer
The early days of laboratory research on metformin’s anti-cancer mechanisms 
focused mainly on its metabolic effects on cell proliferation, which naturally 
follows from the initial use of metformin as a treatment for T2DM as a meta-
bolic disorder. Eventually, it became gradually apparent that unlike modern day 
targeted therapies, metformin’s anti-neoplastic bioactivity is broad ranged and 
pleiotropic, encompassing not only its established metabolic effects, but also 
involving antiangiogenic, anti-inflammatory, epigenetic, apoptotic and autopha-
gic, and immunologic actions as well as effects on the microbiome and on cancer 
stem cells (CSCs) that all synergistically contribute to overall cancer prevention 
and control. Furthermore, within each category of its bioactivity, it further 
exerts multiple molecular actions, and it has thus become increasingly apparent 
that metformin could be properly conceived of as a multi-faceted multi-tasking 
molecule with direct and indirect actions against cancer. In summary, the anti-
cancer effects of metformin is based on 1) its main action on cellular metabolism 
via the maintenance of plasma glucose and insulin levels, 2) targeted action 
against cancer cells with pleiotropic inhibitory effects on multiple pathways 
involved in cancer cell survival and metastasis, and 3) indirect anti-angiogenic 
anti-inflammatory as well as immunomodulatory effects and also its actions on 
the microbiome and CSCs. The complex pleiotropic nature of metformin effects 
on cancer is illustrated in Figure 2.
2.1 Metformin metabolic effects
To understand the metabolic impact of metformin on cancer, we must first 
recognize the intimate relationship between glucose energy metabolism and cel-
lular proliferation as well as a unique propensity of cancer cells to utilize glucose 
anaerobically even in the presence of oxygen in contrast to non-cancer cells which 
utilize oxidative phosphorylation to generate energy. This phenomenon was first 
noted by Otto Warburg almost a hundred years ago, and subsequently termed the 
“Warburg effect” [7]. This altered energy metabolism of cancer cells may underline 
their proliferation, invasiveness, and chemoresistance and this altered metabolic 
pattern in cancer is regulated by oncogenic and tumor suppressor signals such as 
hypoxia inducible factor 1 (HIF-1), myelocytomatosis oncogene cellular homolog 
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(Myc), p53, and the phosphoinositide 3 kinase (PI3K)/AKT8 virus oncogene cellular 
homolog (Akt)/mammalian target of rapamycin (mTOR) pathways.
Metformin’s main pharmacologic action is the reducing elevated plasma glucose 
is largely due to the improvement in hepatic insulin resistance leading to a reduction 
in hepatic glucose output from gluconeogenesis, increases glucose uptake in muscle, 
decreased absorption of sugar from the intestines, and improved insulin sensitiv-
ity, mainly via activation of a cellular energy sensor known as AMP-activated 
protein kinase (AMPK). The major downstream target of AMPK is mTOR, which 
is very important in cellular growth processes and cancer dynamics, and mTOR is 
inhibited by AMPK [8]. Since glucose metabolism is at the center of the metabolic 
derangement that is a hallmark of cancer cells, and metformin chiefly targets 
glucose metabolism, it follows that the altered metabolic pathway may be a target by 
metformin for cancer prevention or therapy.
It is through its main effects above on metabolism and cellular energetics that 
metformin can attenuate cancer cell proliferation (See Figure 3). Furthermore, 
these metabolic effects in turn impact the immune system, epigenetics, inflam-
mation, cellular apoptotic and autophagic pathways as well as the microbiome and 
CSCs which all play a role in cancer development..
2.2 Metformin immuno-modulatory effects
The immune system participates broadly in the prevention and control of 
cancer and interacts with biological pathways of metabolism and inflammation, 
Figure 2. 
Representation of some of the pleiotropic direct and indirect anticancer effects of metformin as illustrated 
by molecular and cellular pathways. Metformin effects key energy and metabolic processes such as the 
mitochondrial respiration (complex I), TCA cycle, fatty acid β-oxidation, gluconeogenesis, and glycolysis. 
Metformin affects the cell cycle, cell growth, immune response, autophagy, and apoptosis, angiogenesis and 
cancer stem cells. Abbreviations: 4EBP1, 4E-binding protein 1; ACC, acetyl-CoA carboxylase; AKT, AKT 
serine/threonine kinase 1; AMPK, AMP-activated protein kinase; BCL2, apoptosis regulator, BCL2; CCND1, 
cyclin D1; CSC, cancer stem cell; DDIT4, DNA damage inducible transcript 4; EMT, epithelial-to-mesenchymal 
transition; FOXO3, forkhead box O3; GPDH, glycerol-3-phosphate dehydrogenase; IPMK, inositol polyphosphate 
multikinase; LKB1, liver kinase B1; miRNA, micro RNA; mTORC1, target of rapamycin complex 1; SREBF1, 
sterol regulatory element binding transcription factor 1; STAT3, signal transducer and activator of transcription 
3; TCA, tricarboxylic acid; TGFB1, transforming growth factor beta 1; VEGF, vascular endothelial growth 
factor. Phosphorylated molecules are indicated by a prefix p. source: [6], Licensed under CC BY 4.0.
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and metformin again acts in a multifaceted fashion to bolster immunity against 
cancer with effects on almost every aspect of the immune system, especially 
with reference to cancer immunty (Figure 4). One of metformin’s actions is the 
enhancement of CD8+ T lymphocytes and rescues them from exhaustion. CD8+ 
T cells which is one of the key components in cellular immunity against tumors, 
as these cells can expand and transform into effector cytotoxic T lymphocytes 
(CTL) which targets cancer. This phenomenon of the rescue of exhausted CD8+ 
T lymphocytes has been confirmed in vitro in leukemia, melanoma, renal cell 
carcinoma, non–small-cell lung carcinoma (NSCLC), gastrointestinal carci-
noma, and breast cancer. Also, metformin-induced activation of AMPK as one 
of its main metabolic actions mentioned above promotes immune check-point 
programmed death ligand 1 (PD-L1) degradation, which allows CTL-mediated 
tumor cell death [11]. Additionally, metformin can also enhance local as well as 
systemic cytokine responses to tumors [12]. Furthermore, metformin also has 
indirect effects on the immune system via its influence on the microbiome and its 
anti-inflammatory effects, which has been reviewed exhaustively and is briefly 
summarized below.
Figure 3. 
The effect of metformin in suppressing cancer cell growth via metabolic pathways. Metformin inhibits 
complex I of the electron transport chain, which leads to increased AMP/ATP ratio and activation of AMPK 
by LKB1. Activated AMPK subsequently inhibits mTOR and its downstream targets by the following two 
pathways: 1. AMPK stabilizes TSC1/2, which inhibits Rheb, an activator of mTOR; 2. AMPK inhibits mTOR 
binding protein raptor. Metformin directly inhibits mTOR by up-regulating REDD1 and suppressing rags. 
AMPK, AMP-activated protein kinase; Rheb, Ras homolog enriched in brain; LKB1, liver kinase B1; REDD1, 
regulated in development and DNA damage response 1; TSC, tuberous sclerosis complex; rags, rag GTPases; 
mTOR, mammalian target of rapamycin; 4EBP1, eukaryotic initiation factor 4E binding protein 1; S6K, S6 
kinase. Source: [9], Licensed under CC BY 3.0.
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2.3 Metformin effects on the microbiome
Whereas science has become increasingly aware of the central role the gut 
microbiome plays in health and diseases including cancer, particularly via its effects 
on the immune system [13], metformin’s beneficial role on host metabolism has 
also been found to be in part related to the microflora in the gut. The microbiome 
modulates our immune system and inflammatory response and both of these are 
key factors in determining cancer development and are associated with inflam-
matory immune response [14] highlights the crosstalk between metformin effects 
on metabolism, immunity, inflammation and the microbiome, which in turn 
can modulate cancer biodyamanics, and part of the mechanisms involved in this 
complex interplay is illustrated in Figure 5 below.
2.4 Metformin anti-inflammatory effects
Inflammation effects on cancer promotion is well known. In 1863, Rudolf 
Virchow first proposed the role of inflammation in cancer based on the observa-
tion of leukocytes in cancerous tissue. Subsequently, accumulated evidence has 
identified inflammation both as a cause and result of malignancy [16], with numer-
ous studies in past decades implicating chronic inflammation in the promotion 
of malignancy [17] (Figure 6). Not surprisingly then, given the T2DM’s known 
association with chronic low-grade subclinical inflammation which is part and 
parcel of its the insulin resistance that is its hallmark [19], and metformin’s effects 
on the immune and metabolic systems, that metformin must also modulate the 
inflammatory response. This connection has been well demonstrated by animal 
experiments where metformin treated rodents reveal dampened pro-inflammatory 
pathways nuclear factor k B (NF-k) and Jun N-terminal kinase (JNK) and increased 
anti-inflammatory cytokine IL-10 [20].
Figure 4. 
Metformin effects related to anticancer immunity. Metformin indirectly increases T-cell activity by negatively 
regulating (a) chronic inflammation, (B) hypoxia, and (C) PD-L1 levels that inhibit T-cell activity. 
Metformin directly relieves T-cell exhaustion by means of metabolic reprogramming of TIL and promotes 
memory T-cell differentiation (D). Metformin shifts the profile of gut microbiota more favorably to T-cell 
immunity (TAM) tumor-associated macrophages (E); (Mφ) macrophages; (MDSC) myeloid-derived 
suppressor cells; (T) T-cell; (DAMPs) damage-associated molecular patterns; (APC) antigen presenting; 
(SCFA) short-chain fatty acid. Source: [10], CC BY-NC 3.0.
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2.5 Metformin epigenetic effects
Epigenetics is the genomic mechanism that reversibly modulates gene 
expression independent of DNA sequences. Epigenetic processes which allow 
for the gene modulatory effect involve DNA methylation, histone modification, 
Figure 5. 
Crosstalk between metformin action and gut microbiota. GLP1: Glucagon-like peptide-1; GLP2: Glucagon-like 
peptide-2; LPS: Lipopolysaccharide; SCFA: Short-chain fatty acid. Source: [15], Licensed under CC BY-NC 4.0.
Figure 6. 
Inflammatory cytokines released by immune cells within the tumor microenvironment has a direct effect on 
pre-malignant and cancer cells by increasing their proliferation and resistance to cell death and stresses thus 
directly promoting tumor growth and progression. Additionally, inflammatory signals can suppress anti-
tumor immunity via action of regulatory T-cells, myeloid cells and enhance other cancer promoting cells (such 
as fibroblasts, myeloid cells and endothelium of new blood vessels); altogether, these inflammation driven 
changes also significantly contribute to tumor growths and progression. TME: Tumor microenvironment, Treg: 
Regulatory T cells. Source: [18], Licensed under CC BY 3.0.
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the readout of these modifications, chromatin remodeling and the effects of 
noncoding RNA all of which affects cellular activities such as growth and dif-
ferentiation. Thus, epigenetics can in one sense be conceived of as a master 
switch of cancer biological processes. Recently, there has been growing interest 
in epigenetic targeting as a promising therapeutic option for cancer [21]. And 
since cellular metabolism is tightly linked to epigenetic modifications, it is again 
not surprising that metformin as a modulator of cellular metabolism may also 
possess significant epigenetic effects mainly via histone modification  
(Figure 7), which in turn is another avenue whereby metformin may exert its 
anti-cancer effects [9].
2.6 Metformin apoptotic and autophagic effects
Both apoptosis or programmed cell death and autophagy are important 
catabolic and tumor-suppressive pathways that control cell survival and cell death 
and are thus increasingly important therapeutic targets in cancer [22]. While 
apoptosis involves cellular suicide and cell death pathways, autophagy involves 
recycling and degradation of cellular waste which if maladapted and excessive 
can also lead to cell death and there is significant cross-talk between these two 
pathways [23]. In cancer biology, autophagy is cancer suppressive as it facilitates 
the degradation of oncogenic molecules thus pre-empting the development of 
cancers, while apoptosis leads to cellular suicide and limits the survival of cancer 
cells. As a result, defective or inadequate autophagy or apoptosis can both lead to 
cancer. The complexity of the crosstalk between the apoptosis and autophagy is 
illustrated in Figure 8.
In the case of these pathways, metformin has been shown to promote apoptosis 
in a variety of cancers via various biological pathways [24] while also promoting 
autophagy [25] as two other dimensions of its anti-cancer bioactivity.
Figure 7. 
Schematic of histone modifications via metabolic effects of metformin. Glycolysis determines the NAD+/NADH 
ratio, which affects the activity of histone deacetylases to reduce histone acetylation. Source: [9], Licensed under 
CC BY 3.0.
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2.7 Metformin effects on cancer stem cells
CSCs were only identified in the 1990s, and they have been hypothesized to 
persist in tumors as a distinct cell population capable of self-renewal and maybe 
responsible for cancer relapse and metastasis by giving rise to new tumors. These 
CSCs are also believed to be resistant to traditional chemotherapy and radiation. A 
complex regulatory network consisting of microRNAs and Wnt/β-catenin, Notch, 
and Hedgehog signaling pathways control the properties of CSCs. Therefore, the 
development of specific therapies targeting and its regulatory pathways is another 
avenue for improved cancer treatments to prevent relapse and metastases, and 
improve survival [26]. In this regard, metformin has been reported to target CSCs 
perhaps via blunting of the Warburg effect and consequently down-regulates their 
growth. In animal studies, it has been found that metformin exposure was associ-
ated with a ~ 2-fold reduction in ovarian CSCs and increased in chemotherapy 
response and translational studies completed as part of a multi-center phase 2 
clinical trial was able to demonstrate a 2.4-fold CSC reduction as well as improved 
survival in ovarian cancer patients [27].
2.8 Metformin’s antiangiogenic effects
Angiogenesis is the process where a tumor can induce its own blood supply via 
neovascularization to enhance its own nutrient source as well as increase its pro-
pensity to metastasize. It follows that antiangiogenesis which involves the suppres-
sion of vascular supply to tumors may be an effective method of cancer control as 
initially proposed by Folkman [28]. In this regard, preclinical studies with metfor-
min have reported that it indirectly modulates tumor angiogenesis most likely via 
metabolic pathways affecting proangiogenic signals. As an example, metformin is 
known to decrease HIF-1α stability in cancer cells, reducing the expression of HIF-1 
Figure 8. 
Complex crosstalk between autophagy and apoptosis pathways. Various proteins involved at the different 
points of crosstalk are shown and labeled. Lines denote interactions or processes, with solid lines corresponding 
to intrapathway processes and dashed lines corresponding to inter-pathway connections. Red lines denote 
inhibitory interactions, while lines with arrows indicate facilitating interactions. Source: [24], Licensed under 
CC BY 3.0.
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targeted genes and thus resulting in smaller tumor vessel size, reduced microves-
sel density and slower tumor growth [29]. Another murine experiment analyzing 
angiogenesis in a matrigel plug model found that metformin treatment lead to a 
decrease in angiogenesis [30].
3. Deployment strategies for metformin in cancer
Metformin can be used tactically under various scenarios against cancer. It can 
be used as standalone or in combination with other agents for the primary or sec-
ondary prevention of cancer [31], as neoadjuvant or adjuvant cancer therapy [32], 
as maintenance therapy or salvage therapy, or to reduce chemoresistance or enhance 
radiosensitivity [33] as well as for the reduction of side-effects or complications 
[34]. Notably, metformin is usually deployed as an adjunct but not as a sole agent 
except in the case of primary prevention. Since it has such low toxicity and multi-
faceted mechanisms of actions, it is usually integrated with other treatment agents 
and modalities under other scenarios besides primary prevention. The key feature 
of metformin that allows this combinatorial deployment is its low toxicity and its 
synergism with various other agents and modalities, as it has been demonstrated 
both in vitro and in vivo.
3.1 Metformin synergies with other anticancer agents and modalities
Notably, synergisms with metformin has been reported with numerous antican-
cer agents and modalities including chemotherapy [35], targeted drugs [36], and 
radiotherapy [37]. In the past ten years alone, metformin synergism with chemo-
therapies pemetrexed [38], temozolomide [39], cisplatin [40], gemcitabine [41], 
paclitaxel [42], 5FU [43], vincristine [44] with targeted agents erlotinib against 
non-small cell lung cancer [45], imatinib against colon cancer [46], gefitinib against 
bladder cancer [47], trastuzumab against human epidermal growth factor receptor 
2 (HER2) positive breast cancer [48], celecoxib against NSCLC [49], regorafenib 
against liver cancer [50], with everolimus as neuroendocrine cancers [51]; and other 
anticancer agents such as with nelfinavir against cervical cancer [52], propranolol 
against breast cancer [53], 2-deoxyglucose against ovarian cancer [54], arsenic 
trioxide against cholangiocarcinoma [55], and with natural compounds epigallocat-
echin-3-gallate [56], curcumin [57], berberine [58], resveratrol [59].
What is interesting is that different biological mechanisms may be responsible 
for the efficacy of metformin’s combinatorial effects depending on the specific 
combination. For example, regulation of lipid synthesis may underlie metformin 
enhancement of taxanes, pro-apoptotic mechanisms could account for its synergy 
with cisplatin, AMPK/mTOR signaling maybe significant when combined with 
hormonal drugs, and suppression of HIF-1, P glycoprotein (p-gp) and multidrug 
resistance-associated protein 1 (MRP1) expression is thought to be responsible for 
metformin’s synergy with anti-metabolites [60]. In the case of targeted agents such 
as the epidermal growth factor receptor (EGFR) inhibitor gefitinib against NSCLC 
where a Chinese study on diabetic NSCLC patients on gefitinib demonstrated 
significantly improved response rate, disease control rate, median progression 
free survival (PFS) and median overall survival (OS) compared with patients 
controls (70.5% vs. 45.7%, P = 0.017; 97.7% vs. 80.4%, P = 0.009; 19 months vs. 
8 months, P = 0.005; 32 months vs. 23 months, P = 0.002, respectively) [61]. 
Separately, metformin combination with m-TOR inhibitor everolimus in patients 
with advanced pancreatic neuroendocrine tumors showed improved median PFS 
of patients treated with the combination vs. control (median PFS, 20.8 months; 
11
Repurposing of Metformin as a Multifaceted and Multitasking Preventative and Treatment…
DOI: http://dx.doi.org/10.5772/intechopen.96101
hazard ratio, 0.49; 95% confidence interval (CI), 0.34–0.69; P < .0001), suggesting 
that metformin may sensitize everolimus in these patients [62]. As far as combina-
tion with antibody treatments go, a randomized phase II study of metformin plus 
bevacizumab-based chemotherapy in advanced or metastatic NSCLC patients 
resulted in a 47% (95% CI, 25%–88%) one-year PFS in patients on metformin, 
which is much improved over a historical control of 15%. Median overall survival of 
15.9 months of metformin treated patients was also improved over control arm of 
13.9 months [63]. Furthermore, metformin in combination with immune check-
point inhibitors (ICI) has received much recent attention as ICI is increasingly 
being deployed in cancer treatments. A retrospective review of 50 NSCLC patients 
receiving ICIs as second or third line therapy with or without metformin showed 
higher overall response rate, disease control, median OS and PFS in the metformin 
group (41.1 vs. 30.7%, P = 0.4; 70.5 vs. 61.6%, P = 0.5; 11.5 vs. 7.6 months, P = 0.5 
and 4.0 vs. 3.0 months, P = 0.6, respectively) [64]. Very recently, several significant 
trials have been launched to further investigate the role metformin may have in 
combination with ICI’s, including a metformin-nivolumab combination in patients 
with NSCLC (NCT03048500), a phase I trial investigating the combined effect of 
metformin and another anti-PD-L1 antibody durvalamab in head and neck squa-
mous cell carcinoma (NCT03618654), a phase I trial of metformin in combination 
of the anti-PD-1 antibody pembrolizumab in advanced melanoma (NCT03311308), 
and a phase II trial combining metformin with nivolumab in stage IV colorectal 
cancer that has not responded to previous treatment (NCT03800602).
The use of metformin under various scenarios against cancer has been best 
studied clinically for primary prevention and in the neoadjuvant setting and some 
of the relevant data is summarized below.
3.2 Metformin for primary prevention of cancer
Cancer prevention is the earliest role that metformin was hypothesized to play in 
the disease as it was Evans’ original 2005 retrospective case–control study demon-
strating metformin’s involvement in reducing cancer risk in T2DM that highlighted 
its potential for cancer [4]. Subsequently, a confirmative cohort study of T2DM 
with metformin followed in which the frequency of cancer was significantly lower 
in patients receiving metformin versus controls who had never received metformin, 
after adjusting for body mass index, hemoglobin A1C, smoking and the use of 
other drugs [65], a finding that was subsequently repeatedly confirmed. Indeed, 
meta-analyses have demonstrated that metformin is associated with a decreased 
risk of breast, colon, liver, pancreas, prostate, endometrium and lung cancer across 
meta-analyses [31] suggesting that people with T2DM receiving metformin dem-
onstrate a lower risk and improved outcomes with most common cancers; more 
specifically one meta-analysis found that metformin-treated T2DM patients had a 
31% reduction in the incidence of cancer and a 34% reduction in cancer mortality 
after adjusting for body mass index [66].
3.3 Metformin in neoadjuvant treatment
Neoadjuvant effects of metformin in combination or alone has been clinically 
explored in several cancers types. In one study of two hundred eighty-five patients 
with esophageal adenocarcinoma treated with concurrent chemoradiation followed 
by esophagectomy, complete remission (CR) was higher in T2DM patients taking 
metformin (34.5%) compared to those who are not (4.8%, P = 0.01) as well as non-
diabetic patients who are not on the drug (19.6%, P = 0.05) and furthermore the CR 
rate was found to be related to metformin dose, with ≥1500 mg per day associated 
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with a higher CR rate [67]. In a separate study of diabetic rectal cancer patients 
undergoing neoadjuvant chemoradiotherapy, those on metformin experienced 
better tumor responses (P = 0.002), pathologic complete remission (p = 0.037), 
and N downstaging (P < 0.001) as well as experienced improved cancer specific 
survival and lower risk of recurrence [68]. Separately, women with endometrial 
cancer on neoadjuvant metformin 850 mg twice daily for an average of 20 days 
between diagnosis and surgery had reduced cell proliferation per Ki-67 expres-
sion, compared to the untreated [69]. A similar biomarker based on a “window 
of opportunity” assessment of metformin 500 mg three times daily for a median 
duration of 18 days in non-diabetic breast cancer also demonstrated that short-term 
preoperative metformin resulted in both clinical and cellular changes including a 
significant decrease in the Ki-67 proliferation index from 36.5 to 33.5% (P = 0.016) 
[70]. Separately and perhaps more significantly, a study involving early-stage breast 
cancer assessing remission rates after neoadjuvant therapy among metformin vs. 
non-metformin users found a significant difference in CR of 24% in the metformin 
group, 8.0% in the non-metformin group, and 16% in the non-diabetic group, 
with metformin use independently predictive of response (OR 2.95; P = 0.04) after 
adjustment for diabetes, body mass index, age, stage, grade, receptor status, and 
neoadjuvant chemotherapy use by multivariate logistic regression [71].
4.  Systematic reviews and meta-analyses on metformin clinical 
outcomes in various cancers
Since metformin is so versatile and has been studied in a wide variety of settings 
from the laboratory to bedside, and since this review is intended to focus on the 
clinical deployment of metformin, it is thus useful to have a summary perspective 
of its potential usefulness in cancer by reviewing clinical results as recently meta-
analyzed for various cancers.
4.1 Bladder cancer
A review of 9 retrospective cohort studies with 1,270,179 patients did not reveal 
a benefit from metformin in preventing bladder cancer (Hazard ratio (HR) = 0.82, 
95% CI = 0.61–1.09; P = .17). However, metformin intake was associated with 
an improved recurrence-free survival (HR = 0.55, 95% CI = 0.35–0.88; P = .01), 
progression-free survival (HR = 0.70, 95% CI = 0.51–0.96; P = .03), as well as 
cancer-specific survival (HR = 0.57, 95% CI = 0.40–0.81; P = .002) [72].
4.2 Breast cancer
There have been a number of studies relating to metformin’s effect on bio-
markers in breast cancer patients and it has been shown that metformin therapy 
reduced the levels of insulin, sex hormones and sex hormone-binding globulin, 
Ki67, caspase-3, p-Akt, obesity, CRP, blood glucose and lipid profile overall [73]. 
More, in a clinical trial to examine the clinical and biological effects of neoadjuvant 
metformin on patients with breast cancer, non-diabetic women with untreated 
breast cancer given 500 mg of metformin three times daily for ≥2 weeks exhibited 
decreased insulin receptor expression (P = 0.04), phosphorylation status of protein 
kinase B /Akt, extracellular signal-regulated kinase 1/2, AMPK and acetyl coen-
zyme A carboxylase (P = 0.0001, P < 0.0001, P < 0.005 and P = 0.02, respectively) 
in tumors correlating with decreases in tumor cell proliferation and increases in 
apoptosis [74]. In T2DM patients with breast cancer, a 2018 meta-analysis of eleven 
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studies of all-cause mortality found a 45% risk reduction was observed for all-cause 
mortality (HR = 0.55; 95% CI 0.44–0.70) and concluded that metformin may 
improve overall survival in this patient subset [75]. Separately in another review, 7 
observational studies showed significantly reduced breast cancer risk among T2DM 
patients on metformin OR = 0.83 (CI 0.71–0.97) [76]. Separately, in a sub-study 
involving over four hundred diabetic patients in the large phase 3 ALTTL trial of 
Her2+ breast cancer patients, Her2+ and estrogen receptor positive breast cancer 
cases on metformin experienced had improved disease free survival, metastasis free 
disease survival and overall survival over those patients not on metformin over a 
median of four and a half years [77]. However despite the vast amount of preclini-
cal and epidemiologic data on its benefits in breast cancer, there are no trials in 
non-diabetic breast cancer patients to date which have unequivocally demonstrated 
a clinical benefit of metformin.
4.3 Colon cancer
Ng et al. from Singapore found 58 studies that provided incidences of colorectal 
adenoma and cancer and cancer survival outcomes and found that metformin 
significantly lowered the risk of colorectal adenoma (RR 0.77, CI 0.67–0.88, 
P < 0.001), advanced adenoma (0.61, CI 0.42–0.88, P = 0.008) and colorectal 
cancer (RR 0.76, CI 0.69–0.84, P < 0.001) respectively. Overall cancer survival (HR 
0.6, CI 0.53–0.67, P < 0.001), even among metastatic cases was also higher among 
metformin users (HR 0.77, CI 0.68–0.87, P < 0.001), and it was concluded that 
metformin significantly reduces colorectal adenoma and cancer incidence as well as 
enhanced colorectal cancer survival at all stages [78].
4.4 Endometrial cancer
In 19 studies reviewed in 2017, metformin used reversed atypical endometrial 
hyperplasia to normal, and decreased cell proliferation from 51.94% (CI = 36.23% 
to 67.46%) to 34.47% (CI = 18.55% to 52.43%) [79], while separately, a review of 
seven studies showed that metformin could significantly improve overall survival 
of in endometrial cancer (HR = 0.61, 95% CI 0.48–0.77, P < 0.05) and reduce their 
recurrence risk (OR = 0.50, 95% CI 0.28–0.92, P < 0.05) [80], whereas another 
review of six retrospective cohorts if 4723 endometrial cancer cases demonstrated 
that metformin use was associated with a significant reduction in overall mortality 
in comparison with not using metformin (adjusted HR 0.64, 95% CI 0.45–0.89, 
P = 0.009) irrespective of diabetic status [81], and these results corroborated the 
improved overall (HR, 0.58; 95% CI, 0.45–0.76; P = 0.207) as well as progression 
free survival (HR, 0.61; 95% CI, 0.49–0.76; P = 0.768) found in another review of 
6242 patients from fourteen studies [82].
4.5 Lung cancer
An analysis of 13 observational studies found lung cancer incidence to be 
reduced in diabetic patients on metformin vs. no metformin (RR = 0.89; 95% 
CI, 0.83–0.96; P = 0.002) [83]. A separate meta-analysis found six studies 
comparing metformin usage and non-metformin usage significantly improved 
overall survival in diabetic patients with NSCLC [pooled HR =0.87 (0.77–0.99), 
P = 0.04] [84]. Especially noteworthy was an ambitious prospective clinical 
trial conducted by Marrone et al. which studied non-diabetics with advanced or 
metastatic NSCLC receiving platinum-based doublet chemotherapy and bevaci-
zumab with or without metformin 1000 mg twice daily followed by maintenance 
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therapy with bevacizumab and metformin combined or bevacizumab alone and 
showed a significant clinical benefit in PFS (9.6 vs. 6.7 months) with the addition 
of metformin [63].
4.6 Pancreas cancer
A review of seventeen studies involving 36791 participants study has evidenced 
a significant association of metformin adjuvant treatment in pancreas cancer with 
overall survival benefit (HR = 0.88, 95% CI = 0.80–0.97) especially in Asians, those 
with early stage disease and those undertaking surgery [85]. In terms of overall 
survival with metformin use in pancreas cancer, a study of 8 retrospective cohort 
studies and 2 randomized clinical trials representing 3,042 patients revealed overall 
survival to be improved with metformin (meta-HR = 0.79; 95% CI: 0.70, 0.92, 
P < 0.001) [86].
4.7 Prostate cancer
In a systematic review involving eleven studies with 877,058 patients, the odds 
ratio of metformin use for reducing prostate cancer was estimated at 0.89 (95%CI: 
0.67–1.17) and it was concluded that metformin consumption reduced the risk of 
prostate cancer, although the result was not statistically significant [87]. Separately, 
a review of eight studies on diabetic patients with prostate cancer found no met-
formin use was associated with an increased risk of cancer recurrence (RR, 1.20; 
95%CI, 1.00–1.44) [88], which concurs with another review of eight retrospective 
cohort studies and one nested-case–control study, metformin was found to be 
associated with a reduced risk of biochemical recurrence (pHR: 0.82, 95% CI 0.67, 
1.01, P = 0.06) [89]. Finally, a large review of 30 cohort studies, including 1,660,795 
prostate cancer patients revealed that metformin treatment compared with no 
treatment improved overall, prostate cancer specific, and recurrence free survival 
(HR = 0.72, 95% CI: 0.59–0.88, P = 0.001; HR = 0.78, 95% CI: 0.64–0.94, P = 0.009; 
and HR = 0.60, 95% CI: 0.42–0.87 P = 0.006, respectively) [90].
4.8 Ovarian cancer
One review of 13 studies involving ovarian cancer incidence and prognosis revealed 
metformin use to be associated with a lower incidence (pooled OR 0.76, 95% CI 0.62 
to 0.93, P = 0.008) as well as improved prognosis (pooled OR 0.55, 95% CI 0.36 to 
0.84, P = 0.006) [91].
4.9 Other cancers
Metformin is also increasingly studied or planned in less common cancers, such 
as glioblastoma, thyroid cancer, and non-Hodgkin’s lymphoma. The recent study 
on newly diagnosed glioblastoma showed that temozolomide plus memantine, 
mefloquine, and metformin are feasible as an adjuvant therapy [92]. One planned 
phase 1b/2 clinical trial of metformin and chloroquine was recruiting patients with 
IDH1-mutated or IDH2-mutated solid tumors, including glioma [93]. In another 
recent retrospective study from Korea, cancer preventative effects of metformin on 
thyroid cancer were observed in individuals with T2DM on long duration or higher 
doses of the drug [94]. Separately, a trial in head and neck squamous cell cancer 
patients revealed metformin to inhibit cancer by enhancing apoptosis, and increas-
ing cellular immune infiltration of the cancer [95]. In non-Hodgkin’s lymphoma, a 
retrospective analysis of looking at T2DM patients treated with standard therapy 
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found improved progression-free survival and overall survival compared to control 
not taking metformin [96].
5. Discussion
Any discussion of a therapeutic agent is incomplete without covering its toxicity, 
side-effects and drug interactions. In this regard, metformin is probably one of the 
safest drugs in use, especially when compared with standard anti-cancer agents in 
its context as a potential cancer preventative or therapeutic. With its long history of 
widespread use, its pharmacokinetics and toxicity profile are well established. The 
most common side-effect is mild to moderate gastrointestinal discomfort or diar-
rhea which is usually self-limited and can be minimized if metformin is taken with 
food, while its most serious side-effect of lactic acidosis usually due to overdose is 
relatively rare, occurring once per 100,000 years of use or 3 case per 1,000,000 
after long term treatment [97]. As in the case of all medications, it should be 
dispensed carefully in elderly patients and in those with impaired renal, cardiac, 
and hepatic function. For practical purposes, it needs to be emphasized that metfor-
min as an antidiabetic and as monotherapy does not cause hypoglycemia or weight 
gain, unlike insulin or sulfonylureas. For cancer, because of its very common use 
in diabetics, it has practically seen combined use with most oncologic agents in the 
diabetic cancer patient and remarkably no serious interactions with standard cancer 
anti-cancer agents have been reported. The minimum toxic dose of metformin is not 
well defined, but rare case reports of severe toxicity has only been reported after 
ingestion of 25 to 35 grams of metformin by adults.
A treatment for any condition is ideal if it relatively non-toxic and scientifically 
well evidenced, as well as low in cost and convenient to administer. Metformin 
fits all the above criteria. It is apparent from our review that metformin has ample 
scientific evidence from bench to the bedside as a repurposed drug for cancer. In 
fact, it is safe to say that it is currently the most well evidenced repurposed drug 
for cancer. Also, its wide-spread and decades of experience of clinical use and low 
observed toxicities alone or in combination with other agents, as well as very low 
cost also marks it as an optimal therapeutic agent. Finally, the versatility it possesses 
against various cancers and its applicability from prevention to treatment further 
distinguishes it as an ideal or model repurposed drug for cancer.
Of course, there remains limitations and challenges to metformin’s use as an 
anticancer. The first obstacle we have in translating in vitro results of metformin 
to the clinical arena revolves around its dosage. The usual dosage of metformin in 
cancer trials is the same range as that prescribed normally for T2DM which is from 
1000 mg – 2000 mg per day. Treatment is usually started at the lower dose with 
dose escalations weekly to the maximum dose which means starting at 500 mg of 
the immediate release version twice daily or 850 mg of the extended release ver-
sions once daily, with 500 mg increments weekly as tolerated, to a maximum of 
2000–2550 mg per day for either immediate or extended release versions. It may not 
be apparent at first glance, but the concentration of metformin at 10–100 microM 
when used clinically at 1000-2000 mg per day is much less than the concentration 
of >2–5 mM demonstrated for its anti-cancer effects in vitro where metformin was 
usually experimented at concentrations between 5 to 20 mM, which is 2 000–10 
000 times more concentrated than achieved with clinical dosing [98]. Fortunately, 
many clinical studies still yielded positive results at the much lower metformin 
in concentrations achieved with clinical dosing, but it may also explain why the 
clinical results of metformin in cancer may not be as dramatic as demonstrated 
in preclinical studies, and why it is never intended to be used as monotherapy for 
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cancer treatment. Related to dosing is a possible dose-dependent effect of metfor-
min on cancer risk [99], which raises the question of attempting higher doses of 
metformin in future clinical trials of metformin in cancer, this while taking into 
account that there are no cases of acute metformin overdose leading to death found 
in which patients with a peak serum metformin concentration is under 50 microg/
mL [100]. Beyond dosing, another issue with the literature to date on metformin 
and cancer is that most of the clinical studies so far are retrospective that mainly 
involve observations in the T2DM patient population and thus subject to selection 
bias. However, many cohort studies in the non-diabetic is planned, and despite 
methodological limitations, it is apparent that the overwhelming evidence so far is 
in favor of potential benefits and a high benefit to risk and benefit to cost ratios for 
metformin’s application in cancer.
6. Conclusion
As an old repurposed drug, metformin is inexpensive and generic and its 
research is thus carried out usually without industry support. Despite such chal-
lenges, it is heartening that overall preclinical and clinical results is overwhelm-
ingly suggestive of a protective effect from metformin against various stages of 
a wide spectrum of cancers. Moreover, there are over three hundred registered 
clinical trials on metformin and cancer internationally as of mid-2020, of which 
approximately one third are actively recruiting. The trials involve metformin for 
pre-cancers, early stage as well as metastatic solid tumors, alone or in combination 
with other interventions including chemotherapy, radiotherapy, hormone therapy, 
immunotherapy (ICIs), targeted agents, statins, aspirin, doxycycline, nelfinavir, 
melatonin, disulfiram, vitamin C, diet in diabetics and non-diabetics. We thus look 
forward for the further establishment of metformin as an ideal repurposed agent 
for cancer prevention and treatment.
Acronyms and abbreviations
Akt AKT8 virus oncogene cellular homolog
AMPK AMP-activated protein kinase
CI confidence interval
CR complete remission
CSC cancer stem cell
CTL cytotoxic T lymphocytes
EGFR epidermal growth factor receptor
GPDH glycerol-3-phosphate dehydrogenase
HER2 human epidermal growth factor receptor 2
HIF hypoxia inducible factor; HR: hazard ratio
hs-CRP C-reactive protein
ICI immune checkpoint inhibitor
JNK Jun N-terminal kinase
mTOR mammalian target of rapamycin
MRP-1 multidrug resistance-associated protein 1
Myc myelocytomatosis oncogene cellular homolog
NAD+/NADH nicotinamide adenine dinucleotide (oxidized)/nicotinamide 
adenine dinucleotide + hydrogen
NF-kB nuclear factor k B
NSCLC non-small cell lung cancer
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OS overall survival
PD-1 programmed cell death protein 1
PD-L1 programmed death-ligand 1
p-gp P glycoprotein
PI3K phosphoinositide 3 kinase
PFS progression free survival
T2DM type 2 diabetes mellitus
Treg regulatory T cell
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